Stem cell factor-induced downregulation of c-kit in human lung mast cells and HMC-1 mast cells

Autor: Baghestanian M, Agis H, Bevec D, Hc, Bankl, Hofbauer R, Hg, Kress, Jh, Butterfield, Müller MR, Lk, Ashman, Füreder W, Willheim M, Lechner K, Peter Valent

Publikováno v: Europe PubMed Central
ResearcherID

Recent data suggest that local overexpression of the tissue-hormone c-kit ligand (stem cell factor [SCF]) is associated with accumulation of mast cells (MCs) and a decrease in expression of c-kit in the accumulated MCs [28]. In the present study, the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::84fbc747bc4406f31442f4963526aba4
https://pubmed.ncbi.nlm.nih.gov/8913283

THE ROLE OF STROMA CELLS ON THE PROLIFERATION AND C-KIT EXPRESSION OF ACUTE MYELOBLASTIC-LEUKEMIA CELLS

Autor: Shuji Tohda, Lk Ashman, Minden

Publikováno v: International Journal of Oncology.

To examine the role of stroma cells on the proliferation and c-kit expression of acute myeloblastic leukemia (AML) cells, blast cells from patients were cultured with growth factors or on human marrow stroma cells. c-KIT protein detected by flow cyto

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1848bccb46b392745c3033c33c8d02e6
https://doi.org/10.3892/ijo.3.6.1141

IL-4 regulates c-kit proto-oncogene product expression in human mast and myeloid progenitor cells

Autor: Sillaber C, Herbert Strobl, Bevec D, Lk, Ashman, Jh, Butterfield, Lechner K, Maurer D, Bettelheim P, Valent P

Publikováno v: Europe PubMed Central

The c-kit proto-oncogene encodes the receptor for a novel hemopoietic cytokine, termed stem cell factor (SCF) or mast cell growth factor (MGF) according to its stimulating spectrum. The human receptor for SCF/MGF is expressed in a subset of normal bo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a3147ca4caa9f57d7c6f444e108a201
http://europepmc.org/abstract/med/1721642

miR-518f-5p decreases tetraspanin CD9 protein levels and differentially affects non-tumourigenic prostate and prostate cancer cell migration and adhesion.

Autor: Bond DR; School of Biomedical Science and Pharmacy, The University of Newcastle and Hunter Medical Research Institute (HMRI), NSW, Newcastle, Australia.; School of Environmental and Life Sciences, The University of Newcastle and Hunter Medical Research Institute (HMRI), NSW, Newcastle, Australia., Naudin C; School of Biomedical Science and Pharmacy, The University of Newcastle and Hunter Medical Research Institute (HMRI), NSW, Newcastle, Australia.; Department of Pediatrics, Emory University, Atlanta, GA, USA., Carroll AP; School of Biomedical Science and Pharmacy, The University of Newcastle and Hunter Medical Research Institute (HMRI), NSW, Newcastle, Australia.; Schizophrenia Research Institute, Sydney, NSW, Australia., Goldie BJ; School of Biomedical Science and Pharmacy, The University of Newcastle and Hunter Medical Research Institute (HMRI), NSW, Newcastle, Australia.; Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia., Brzozowski JS; School of Biomedical Science and Pharmacy, The University of Newcastle and Hunter Medical Research Institute (HMRI), NSW, Newcastle, Australia., Jankowski HM; School of Biomedical Science and Pharmacy, The University of Newcastle and Hunter Medical Research Institute (HMRI), NSW, Newcastle, Australia., Cairns MJ; School of Biomedical Science and Pharmacy, The University of Newcastle and Hunter Medical Research Institute (HMRI), NSW, Newcastle, Australia.; Schizophrenia Research Institute, Sydney, NSW, Australia., Ashman LK; School of Biomedical Science and Pharmacy, The University of Newcastle and Hunter Medical Research Institute (HMRI), NSW, Newcastle, Australia., Scarlett CJ; School of Environmental and Life Sciences, The University of Newcastle and Hunter Medical Research Institute (HMRI), NSW, Newcastle, Australia., Weidenhofer J; School of Biomedical Science and Pharmacy, The University of Newcastle and Hunter Medical Research Institute (HMRI), NSW, Newcastle, Australia.

Publikováno v: Oncotarget [Oncotarget] 2017 Dec 07; Vol. 9 (2), pp. 1980-1991. Date of Electronic Publication: 2017 Dec 07 (Print Publication: 2018).

Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors.

Autor: Smith AM; School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia.; Hunter Medical Research Institute, Newcastle, New South Wales, Australia.; Current address: The University of Queensland Diamantina Institute, Woolloongabba, Queensland, Australia., Dun MD; School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia.; Hunter Medical Research Institute, Newcastle, New South Wales, Australia., Lee EM; Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW, Sydney, New South Wales, Australia., Harrison C; School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia.; Hunter Medical Research Institute, Newcastle, New South Wales, Australia., Kahl R; School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia.; Hunter Medical Research Institute, Newcastle, New South Wales, Australia., Flanagan H; School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia.; Hunter Medical Research Institute, Newcastle, New South Wales, Australia., Panicker N; School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia.; Hunter Medical Research Institute, Newcastle, New South Wales, Australia., Mashkani B; School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia.; Hunter Medical Research Institute, Newcastle, New South Wales, Australia.; Current address: Department of Medical Biochemistry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran., Don AS; Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales, Australia., Morris J; School of Chemistry, University of New South Wales, Sydney, New South Wales, Australia., Toop H; School of Chemistry, University of New South Wales, Sydney, New South Wales, Australia., Lock RB; Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW, Sydney, New South Wales, Australia., Powell JA; Centre for Cancer Biology, SA Pathology, Adelaide, South Australia, Australia., Thomas D; Centre for Cancer Biology, SA Pathology, Adelaide, South Australia, Australia.; Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California, USA., Guthridge MA; Department Clinical Haematology, Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria, Australia., Moore A; Translational Research Institute, The University of Queensland Diamantina Institute, Woolloongabba, Queensland, Australia., Ashman LK; School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia.; Hunter Medical Research Institute, Newcastle, New South Wales, Australia., Skelding KA; School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia.; Hunter Medical Research Institute, Newcastle, New South Wales, Australia., Enjeti A; School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia.; Hunter Medical Research Institute, Newcastle, New South Wales, Australia.; Calvary Mater Hospital, Newcastle, New South Wales, Australia., Verrills NM; School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia.; Hunter Medical Research Institute, Newcastle, New South Wales, Australia.

Publikováno v: Oncotarget [Oncotarget] 2016 Jul 26; Vol. 7 (30), pp. 47465-47478.